secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2026-06-30T20:57:55+00:00
Accession:  0001193125-26-290768
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma: Vamorolone Phase 1 shows glucocorticoid activity without immunosuppression at clinical doses
--------------------------------------------------------------------------------

- Phase 1 study: vamorolone 300 mg vs deflazacort 0.9 mg/kg showed comparable cortisol suppression.
- No significant immunosuppressive effects at clinical doses (9 or 27 mg/kg/day); only at 40 mg/kg/day.
- Data support current vamorolone dosing in DMD and potential for broader chronic inflammatory indications.
- Study enrolled 24 healthy adults (Part A) and 36 volunteers (Part B) with ascending doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/0001193125-26-290768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526290768/d158010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-290768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer